Form 4: Astria Therapeutics Director, Joanne T. Beck, Reports Stock Option Grant

Joanne T. Beck, a director of Astria Therapeutics, Inc., reported the acquisition of stock options on June 5, 2024.

Summary

• On June 6, 2024, Joanne T. Beck, a director of Astria Therapeutics, Inc., filed a Form 4 with the SEC.
• The report details the grant of stock options to Beck on June 5, 2024.
• Beck acquired options to purchase 14,100 shares of Astria Therapeutics common stock at an exercise price of $9.18 per share.
• The options vest in full on June 4, 2025, contingent upon continued service as a director.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (stock option grant) and doesn't contain any overtly positive or negative information. It's a neutral event with a slightly positive implication due to aligning director incentives.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing her to work towards the company's success.

Future Outlook

The director's continued service is required for the options to vest, indicating an expectation of ongoing involvement with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management and board member interests with shareholder value.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders.

Key Dates